Literature DB >> 16107720

CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.

Kei Ohnuma1, Tadanori Yamochi, Masahiko Uchiyama, Kunika Nishibashi, Satoshi Iwata, Osamu Hosono, Hiroshi Kawasaki, Hirotoshi Tanaka, Nam H Dang, Chikao Morimoto.   

Abstract

CD26 is a T-cell costimulatory molecule with dipeptidyl peptidase IV enzyme activity in its extracellular region. We have previously reported that the addition of recombinant soluble CD26 resulted in enhanced proliferation of human T lymphocytes induced by the recall antigen tetanus toxoid (TT) via upregulation of CD86 on monocytes and that caveolin-1 was a binding protein of CD26, and the CD26-caveolin-1 interaction resulted in caveolin-1 phosphorylation (p-cav-1) as well as TT-mediated T-cell proliferation. However, the mechanism involved in this immune enhancement has not yet been elucidated. In the present work, we perform experiments to identify the molecular mechanisms by which p-cav-1 leads directly to the upregulation of CD86. Through proteomic analysis, we identify Tollip (Toll-interacting protein) and IRAK-1 (interleukin-1 receptor-associated serine/threonine kinase 1) as caveolin-1-interacting proteins in monocytes. We also demonstrate that following stimulation by exogenous CD26, Tollip and IRAK-1 dissociate from caveolin-1, and IRAK-1 is then phosphorylated in the cytosol, leading to the upregulation of CD86 via activation of NF-kappaB. Binding of CD26 to caveolin-1 therefore regulates signaling pathways in antigen-presenting cells to induce antigen-specific T-cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107720      PMCID: PMC1190283          DOI: 10.1128/MCB.25.17.7743-7757.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

1.  A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain.

Authors:  Susan C Shih; Gali Prag; Smitha A Francis; Myra A Sutanto; James H Hurley; Linda Hicke
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

2.  Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells.

Authors:  Yuichi Makino; Hiroshi Nakamura; Eiji Ikeda; Kei Ohnuma; Kenji Yamauchi; Yutaka Yabe; Lorenz Poellinger; Yasunori Okada; Chikao Morimoto; Hirotoshi Tanaka
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

Review 3.  Of mice and not men: differences between mouse and human immunology.

Authors:  Javier Mestas; Christopher C W Hughes
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

4.  CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.

Authors:  Kei Ohnuma; Tadanori Yamochi; Masahiko Uchiyama; Kunika Nishibashi; Noritada Yoshikawa; Noriaki Shimizu; Satoshi Iwata; Hirotoshi Tanaka; Nam H Dang; Chikao Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-07       Impact factor: 11.205

5.  Characterization of Tollip protein upon Lipopolysaccharide challenge.

Authors:  Tao Li; Jean Hu; Liwu Li
Journal:  Mol Immunol       Date:  2004-05       Impact factor: 4.407

Review 6.  Caveolae: mining little caves for new cancer targets.

Authors:  Lucy A Carver; Jan E Schnitzer
Journal:  Nat Rev Cancer       Date:  2003-08       Impact factor: 60.716

7.  Histological features of skin reactions to human lymphoid cell line lymphokine in patients with advanced cancer.

Authors:  D C Dumonde; M S Pulley; F J Paradinas; B M Southcott; D O'Connell; M R Robinson; F den Hollander; A H Schuurs
Journal:  J Pathol       Date:  1982-12       Impact factor: 7.996

8.  Tollip and Tom1 form a complex and recruit ubiquitin-conjugated proteins onto early endosomes.

Authors:  Yohei Katoh; Yoko Shiba; Hiroko Mitsuhashi; Yuko Yanagida; Hiroyuki Takatsu; Kazuhisa Nakayama
Journal:  J Biol Chem       Date:  2004-03-26       Impact factor: 5.157

9.  Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation.

Authors:  Seiji Kobayashi; Kei Ohnuma; Masahiko Uchiyama; Kouichi Iino; Satoshi Iwata; Nam H Dang; Chikao Morimoto
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

10.  Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4.

Authors:  Kimberly Burns; Sophie Janssens; Brian Brissoni; Natalia Olivos; Rudi Beyaert; Jürg Tschopp
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

View more
  25 in total

Review 1.  Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity.

Authors:  Lu Gan; Liwu Li
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 2.  Caveolin-1: a critical regulator of lung injury.

Authors:  Yang Jin; Seon-Jin Lee; Richard D Minshall; Augustine M K Choi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-19       Impact factor: 5.464

3.  Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth.

Authors:  Qifa Xie; Lu Gan; Jianxia Wang; Ingred Wilson; Liwu Li
Journal:  Mol Immunol       Date:  2007-05-02       Impact factor: 4.407

Review 4.  The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation.

Authors:  Lorna Ringwood; Liwu Li
Journal:  Cytokine       Date:  2008-01-30       Impact factor: 3.861

5.  CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.

Authors:  Ryo Hatano; Kei Ohnuma; Junpei Yamamoto; Nam H Dang; Chikao Morimoto
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

6.  Tollip-induced down-regulation of MARCH1.

Authors:  Marie-Claude Bourgeois-Daigneault; Abdul Mohammad Pezeshki; Tristan Galbas; Mathieu Houde; Martin Baril; Klaus Früh; Abdelaziz Amrani; Satoshi Ishido; Daniel Lamarre; Jacques Thibodeau
Journal:  Results Immunol       Date:  2013-02-20

Review 7.  DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.

Authors:  Jixin Zhong; Andrei Maiseyeu; Stephen N Davis; Sanjay Rajagopalan
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

8.  The interleukin-1 receptor associated kinase 1 contributes to the regulation of NFAT.

Authors:  Dongmei Wang; Stephan Fasciano; Liwu Li
Journal:  Mol Immunol       Date:  2008-08-08       Impact factor: 4.407

9.  Differential regulation of Foxp3 and IL-17 expression in CD4 T helper cells by IRAK-1.

Authors:  Urmila Maitra; Sarah Davis; Christopher M Reilly; Liwu Li
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

10.  DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-κB activation.

Authors:  Xingyun Hu; Shanying Liu; Xiaodan Liu; Jinglu Zhang; Ying Liang; Yan Li
Journal:  Endocrine       Date:  2016-09-09       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.